Clinical data of unrelated HSC donor-recipient pairs
. | . | Nonpermissive mismatch . | . | |
|---|---|---|---|---|
. | Permissive mismatch . | GvH direction . | HvG direction . | |
| No. patients | 63 | 24 | 31 | |
| Donor/recipient sex | ||||
| M/M | 19 | 6 | 12 | |
| M/F | 13 | 4 | 7 | |
| F/M | 14 | 8 | 4 | |
| F/F | 17 | 6 | 8 | |
| Age, y (range) | ||||
| Donor | 37 (21-59) | 36 (21-54) | 34 (22-49) | |
| Recipient | 27 (3-55) | 30 (6-54) | 30 (4-59) | |
| Disease | ||||
| CML | 22 | 9 | 18 | |
| CMML | — | 2 | — | |
| AML | 11 | 4 | 5 | |
| ALL | 22 | 6 | 6 | |
| Myeloma | 2 | 1 | 1 | |
| MDS | 5 | 2 | — | |
| NHL | 1 | — | 1 | |
| Early disease phase at transplantation | 39 | 12 | 21 | |
| Time between diagnosis and transplantation, d (range) | 743 (151-4936) | 695 (71-3480) | 810 (104-2392) | |
| Cells infused, 108/kg (range) | 4.4 (0.9-26.1) | 4.8 (1.5-10.9) | 5.3 (1.7-25.7) | |
| TBI conditioning | 53 | 19 | 24 | |
| GvHD prophylaxis | ||||
| Campath | 19 | 3 | 9 | |
| ATG | 32 | 13 | 11 | |
| GvHD grades II-IV | 17 | 10 | 13 | |
| Failure/nonengraftment | — | 1 | — | |
. | . | Nonpermissive mismatch . | . | |
|---|---|---|---|---|
. | Permissive mismatch . | GvH direction . | HvG direction . | |
| No. patients | 63 | 24 | 31 | |
| Donor/recipient sex | ||||
| M/M | 19 | 6 | 12 | |
| M/F | 13 | 4 | 7 | |
| F/M | 14 | 8 | 4 | |
| F/F | 17 | 6 | 8 | |
| Age, y (range) | ||||
| Donor | 37 (21-59) | 36 (21-54) | 34 (22-49) | |
| Recipient | 27 (3-55) | 30 (6-54) | 30 (4-59) | |
| Disease | ||||
| CML | 22 | 9 | 18 | |
| CMML | — | 2 | — | |
| AML | 11 | 4 | 5 | |
| ALL | 22 | 6 | 6 | |
| Myeloma | 2 | 1 | 1 | |
| MDS | 5 | 2 | — | |
| NHL | 1 | — | 1 | |
| Early disease phase at transplantation | 39 | 12 | 21 | |
| Time between diagnosis and transplantation, d (range) | 743 (151-4936) | 695 (71-3480) | 810 (104-2392) | |
| Cells infused, 108/kg (range) | 4.4 (0.9-26.1) | 4.8 (1.5-10.9) | 5.3 (1.7-25.7) | |
| TBI conditioning | 53 | 19 | 24 | |
| GvHD prophylaxis | ||||
| Campath | 19 | 3 | 9 | |
| ATG | 32 | 13 | 11 | |
| GvHD grades II-IV | 17 | 10 | 13 | |
| Failure/nonengraftment | — | 1 | — | |
The pairs were classified as permissive or nonpermissive in GvH or HvG direction, according to the algorithm from Figure 5. CMML indicates chronic myelomonocytic leukemia; NHL, non-Hodgkin lymphoma; and —, not applicable.